Walking-induced motor fatigability in Multiple Sclerosis: a pilot study on underlying mechanisms and the feasibility of sequential resistance and walking-specific endurance training

Walking-induced motor fatigability in Multiple Sclerosis: a pilot study on underlying mechanisms and the feasibility of sequential resistance and walking-specific endurance training - Walking-induced motor fatigability in MS / MS-walk-I

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON44052

Enrollment

Registered

2015-10-13

Start date

2016-02-22

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS Multiple Sclerosis

Interventions

Patients with MS will receive a sequential exercise program for 4 months, 3x per week, in which the first 8 weeks consist of progressive resistance training (2-3 sets, 8-12 reps, 60-70% 1RM), follow

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria - Definite MS - Age >= 18 - Complain of early occurring fatigue or reduced walking speed during prolonged walking. - Able to walk continuously for 12 minutes without walking aids

Exclusion criteria

Exclusion criteria: Exclusion criteria - Other medical conditions that affect gait (e.g. amputation). - Serious comorbidities precluding high-intensity exercise training - Already participating in a high intensity (>=2 per week), guided exercise protocol. - Pregnancy, given birth previous 6 months, or active pregnancy wish

Design outcomes

Primary

Measure	Time frame
Walking-induced motor fatigability, with the central determinant: ankle push off power.	—

Secondary

Measure	Time frame
Spatiotemporal gait characteristics, energy cost of walking, feasibility outcomes of the pilot intervention and measurement procedures.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)